Trial Profile
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2024 This trial has been Discontinued in Italy (End date : 2023-02-15) according to European Clinical Trials Database record.
- 25 May 2023 Status changed from active, no longer recruiting to completed.
- 01 Aug 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2021.